These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 33039340)

  • 1. The DANish randomized, double-blind, placebo controlled trial in patients with chronic HEART failure (DANHEART): A 2 × 2 factorial trial of hydralazine-isosorbide dinitrate in patients with chronic heart failure (H-HeFT) and metformin in patients with chronic heart failure and diabetes or prediabetes (Met-HeFT).
    Wiggers H; Køber L; Gislason G; Schou M; Poulsen MK; Vraa S; Nielsen OW; Bruun NE; Nørrelund H; Hollingdal M; Barasa A; Bøttcher M; Dodt K; Hansen VB; Nielsen G; Knudsen AS; Lomholdt J; Mikkelsen KV; Jonczy B; Brønnum-Schou J; Poenaru MP; Abdulla J; Raymond I; Mahboubi K; Sillesen K; Serup-Hansen K; Madsen JS; Kristensen SL; Larsen AH; Bøtker HE; Torp-Petersen C; Eiskjær H; Møller J; Hassager C; Steffensen FH; Bibby BM; Refsgaard J; Høfsten DE; Mellemkjær S; Gustafsson F
    Am Heart J; 2021 Jan; 231():137-146. PubMed ID: 33039340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of enalapril, hydralazine plus isosorbide dinitrate, and prazosin on hospitalization in patients with chronic congestive heart failure. The V-HeFT VA Cooperative Studies Group.
    Loeb HS; Johnson G; Henrick A; Smith R; Wilson J; Cremo R; Cohn JN
    Circulation; 1993 Jun; 87(6 Suppl):VI78-87. PubMed ID: 8500244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mild systolic dysfunction in heart failure (left ventricular ejection fraction >35%): baseline characteristics, prognosis and response to therapy in the Vasodilator in Heart Failure Trials (V-HeFT).
    Carson P; Johnson G; Fletcher R; Cohn J
    J Am Coll Cardiol; 1996 Mar; 27(3):642-9. PubMed ID: 8606276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review of isosorbide dinitrate and hydralazine in the management of heart failure in black patients, with a focus on a new fixed-dose combination.
    Cheng JW
    Clin Ther; 2006 May; 28(5):666-78. PubMed ID: 16861089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isosorbide dinitrate and hydralazine in a fixed-dose combination produces further regression of left ventricular remodeling in a well-treated black population with heart failure: results from A-HeFT.
    Cohn JN; Tam SW; Anand IS; Taylor AL; Sabolinski ML; Worcel M;
    J Card Fail; 2007 Jun; 13(5):331-9. PubMed ID: 17602978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hydralazine and isosorbide dinitrate combination improves exercise tolerance in heart failure. Results from V-HeFT I and V-HeFT II. The V-HeFT VA Cooperative Studies Group.
    Ziesche S; Cobb FR; Cohn JN; Johnson G; Tristani F
    Circulation; 1993 Jun; 87(6 Suppl):VI56-64. PubMed ID: 8500241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence for the continued safety and tolerability of fixed-dose isosorbide dinitrate/hydralazine in patients with chronic heart failure (the extension to African-American Heart Failure Trial).
    Yancy CW; Ghali JK; Braman VM; Sabolinski ML; Worcel M; Archambault WT; Franciosa JA
    Am J Cardiol; 2007 Aug; 100(4):684-9. PubMed ID: 17697829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure.
    Cohn JN; Johnson G; Ziesche S; Cobb F; Francis G; Tristani F; Smith R; Dunkman WB; Loeb H; Wong M
    N Engl J Med; 1991 Aug; 325(5):303-10. PubMed ID: 2057035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early and sustained benefit on event-free survival and heart failure hospitalization from fixed-dose combination of isosorbide dinitrate/hydralazine: consistency across subgroups in the African-American Heart Failure Trial.
    Taylor AL; Ziesche S; Yancy CW; Carson P; Ferdinand K; Taylor M; Adams K; Olukotun AY; Ofili E; Tam SW; Sabolinski ML; Worcel M; Cohn JN;
    Circulation; 2007 Apr; 115(13):1747-53. PubMed ID: 17372175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of ACE inhibitors or beta-blockers in patients treated with the fixed-dose combination of isosorbide dinitrate/hydralazine in the African-American Heart Failure Trial.
    Ghali JK; Tam SW; Ferdinand KC; Lindenfeld J; Sabolinski ML; Taylor AL; Worcel M; Curry CL; Cohn JN;
    Am J Cardiovasc Drugs; 2007; 7(5):373-80. PubMed ID: 18041162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. The V-HeFT VA Cooperative Studies Group.
    Francis GS; Cohn JN; Johnson G; Rector TS; Goldman S; Simon A
    Circulation; 1993 Jun; 87(6 Suppl):VI40-8. PubMed ID: 8500238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of serial changes in left ventricular ejection fraction in patients with congestive heart failure. The V-HeFT VA Cooperative Studies Group.
    Cintron G; Johnson G; Francis G; Cobb F; Cohn JN
    Circulation; 1993 Jun; 87(6 Suppl):VI17-23. PubMed ID: 8500235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vasodilators in heart failure. Conclusions from V-HeFT II and rationale for V-HeFT III.
    Cohn JN
    Drugs; 1994; 47 Suppl 4():47-57; discussion 57-8. PubMed ID: 7523062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. African-American Heart Failure Trial (A-HeFT): rationale, design, and methodology.
    Franciosa JA; Taylor AL; Cohn JN; Yancy CW; Ziesche S; Olukotun A; Ofili E; Ferdinand K; Loscalzo J; Worcel M;
    J Card Fail; 2002 Jun; 8(3):128-35. PubMed ID: 12140804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. G-protein beta-3 subunit genotype predicts enhanced benefit of fixed-dose isosorbide dinitrate and hydralazine: results of A-HeFT.
    McNamara DM; Taylor AL; Tam SW; Worcel M; Yancy CW; Hanley-Yanez K; Cohn JN; Feldman AM
    JACC Heart Fail; 2014 Dec; 2(6):551-7. PubMed ID: 25306451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of isosorbide dinitrate and hydralazine in African-Americans with heart failure 9 years after the African-American Heart Failure Trial.
    Ferdinand KC; Elkayam U; Mancini D; Ofili E; Piña I; Anand I; Feldman AM; McNamara D; Leggett C
    Am J Cardiol; 2014 Jul; 114(1):151-9. PubMed ID: 24846808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group.
    Carson P; Ziesche S; Johnson G; Cohn JN
    J Card Fail; 1999 Sep; 5(3):178-87. PubMed ID: 10496190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Effectiveness of Hydralazine-Isosorbide Dinitrate in African-American Patients With Heart Failure.
    Ziaeian B; Fonarow GC; Heidenreich PA
    JACC Heart Fail; 2017 Sep; 5(9):632-639. PubMed ID: 28711446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanism of death in heart failure. The Vasodilator-Heart Failure Trials. The V-HeFT VA Cooperative Studies Group.
    Goldman S; Johnson G; Cohn JN; Cintron G; Smith R; Francis G
    Circulation; 1993 Jun; 87(6 Suppl):VI24-31. PubMed ID: 8500236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure.
    Taylor AL; Ziesche S; Yancy C; Carson P; D'Agostino R; Ferdinand K; Taylor M; Adams K; Sabolinski M; Worcel M; Cohn JN;
    N Engl J Med; 2004 Nov; 351(20):2049-57. PubMed ID: 15533851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.